
SELLAS Life Sciences nears key Phase 3 AML trial results with strong cash position and promising drug GPS.
SELLAS Life Sciences is advancing its acute myeloid leukemia (AML) treatment with its lead drug galinpepimut-S (GPS) approaching pivotal Phase 3 trial results in the REGAL study. The company also progresses another candidate, SLS009, targeting high-r...


